| http://www.w3.org/ns/prov#value | - ical trial material, completing necessary manufacturing process development activities, and being subject to a clinical hold, or suspension or termination of a clinical study, including due to patient safety concerns;; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of planned phase 2
|
